Two decades and more than $200 billion later, AbbVie (NYSE: ABBV) has finally lost its exclusive hold on the US market for biologics based on Humira (adalimumab).
Biosimilars referencing the ground-breaking product, which has revolutionized the treatment of autoimmune disorders such as rheumatoid arthritis - are set to hit the US market this year.
The first wave has now begun, with today’s launch of Amgen’s (Nasdaq: AMGN) option, Amjevita (adalimumab-atto).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze